Cargando…

Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients

BACKGROUND: Obestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Szentpéteri, Anita, Lőrincz, Hajnalka, Somodi, Sándor, Varga, Viktória Evelin, Paragh, György, Seres, Ildikó, Harangi, Mariann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838862/
https://www.ncbi.nlm.nih.gov/pubmed/29506551
http://dx.doi.org/10.1186/s12944-018-0691-y
_version_ 1783304317898326016
author Szentpéteri, Anita
Lőrincz, Hajnalka
Somodi, Sándor
Varga, Viktória Evelin
Paragh, György
Seres, Ildikó
Paragh, György
Harangi, Mariann
author_facet Szentpéteri, Anita
Lőrincz, Hajnalka
Somodi, Sándor
Varga, Viktória Evelin
Paragh, György
Seres, Ildikó
Paragh, György
Harangi, Mariann
author_sort Szentpéteri, Anita
collection PubMed
description BACKGROUND: Obestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated. METHODS: Fifty NDO patients (BMI: 41.96 ± 8.6 kg/m(2)) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16 ± 3.3 kg/m(2)) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). RESULTS: Serum level of obestatin was significantly lower in NDO patients compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p < 0.05). We found significant negative correlations between the level of obestatin and BMI (r = − 0.33; p < 0.001), level of serum glucose (r = − 0.27, p < 0.05), HbA1c (r = − 0.38; p < 0.001) and insulin (r = − 0.34; p < 0.05). Significant positive correlation was found between obestatin level and the levels of ApoA1 (r = 0.25; p < 0.05), large HDL subfraction ratio and level (r = 0.23; p < 0.05 and r = 0.24; p < 0.05), IDL (r = 0.25 p < 0.05) and mean LDL size (r = 0.25; p < 0.05). Serum VLDL ratio and level negatively correlated with obestatin (r = − 0.32; p < 0.01 and r = − 0.21; p = 0.05). In multiple regression analysis obestatin was predicted only by VLDL level. CONCLUSIONS: Based on our data, measurement of obestatin level in obesity may contribute to understand the interplay between gastrointestinal hormone secretion and metabolic alterations in obesity.
format Online
Article
Text
id pubmed-5838862
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58388622018-03-09 Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients Szentpéteri, Anita Lőrincz, Hajnalka Somodi, Sándor Varga, Viktória Evelin Paragh, György Seres, Ildikó Paragh, György Harangi, Mariann Lipids Health Dis Research BACKGROUND: Obestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated. METHODS: Fifty NDO patients (BMI: 41.96 ± 8.6 kg/m(2)) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16 ± 3.3 kg/m(2)) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). RESULTS: Serum level of obestatin was significantly lower in NDO patients compared to controls (3.01 ± 0.5 vs. 3.29 ± 0.6 μg/ml, p < 0.05). We found significant negative correlations between the level of obestatin and BMI (r = − 0.33; p < 0.001), level of serum glucose (r = − 0.27, p < 0.05), HbA1c (r = − 0.38; p < 0.001) and insulin (r = − 0.34; p < 0.05). Significant positive correlation was found between obestatin level and the levels of ApoA1 (r = 0.25; p < 0.05), large HDL subfraction ratio and level (r = 0.23; p < 0.05 and r = 0.24; p < 0.05), IDL (r = 0.25 p < 0.05) and mean LDL size (r = 0.25; p < 0.05). Serum VLDL ratio and level negatively correlated with obestatin (r = − 0.32; p < 0.01 and r = − 0.21; p = 0.05). In multiple regression analysis obestatin was predicted only by VLDL level. CONCLUSIONS: Based on our data, measurement of obestatin level in obesity may contribute to understand the interplay between gastrointestinal hormone secretion and metabolic alterations in obesity. BioMed Central 2018-03-05 /pmc/articles/PMC5838862/ /pubmed/29506551 http://dx.doi.org/10.1186/s12944-018-0691-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Szentpéteri, Anita
Lőrincz, Hajnalka
Somodi, Sándor
Varga, Viktória Evelin
Paragh, György
Seres, Ildikó
Paragh, György
Harangi, Mariann
Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title_full Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title_fullStr Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title_full_unstemmed Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title_short Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
title_sort serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838862/
https://www.ncbi.nlm.nih.gov/pubmed/29506551
http://dx.doi.org/10.1186/s12944-018-0691-y
work_keys_str_mv AT szentpeterianita serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT lorinczhajnalka serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT somodisandor serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT vargaviktoriaevelin serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT paraghgyorgy serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT seresildiko serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT paraghgyorgy serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients
AT harangimariann serumobestatinlevelstronglycorrelateswithlipoproteinsubfractionsinnondiabeticobesepatients